BGI Co-Win (Shenzhen) Private Equity Co., Ltd. (BGI Co-Win) is a private equity firm co-founded by a professional investment team focusing on life health and BGI Group, Founded in 2016, BGI Co-Win.

BGI Co-Win (Shenzhen) Private Equity Co., Ltd. (BGI Co-Win) established in January 2016, is a private equity fund management organization co-founded by Hi-Nice Shine investment team and well-known professional investment teams in the field of life and health such as CAC Capital, Qianhai Huxiao Capital, etc., and Beijing Genomics Institution (well known as BGI Group), one of the world’s leading gene technology companies.

BGI Co-Win focuses on companies with high potential in the life science industry, builds a market-oriented ecological investment platform for life and health industry, and achieve resource sharing and co-win development of industrial resources providers, fund investors and invested companies.

The partner team of BGI Co-Win has more than 20 years of investment and project incubation experience, has fully experienced the fund cycles of fund raising, investment, fund management and fund exit, and has established a mature investment management system.

Under the professional concept of "R&D Driven Investment", BGI Co-Win adheres to the method of "Draw industrial distribution map and actively invest according to the map", and especially focuses on enterprises that master core technologies or platform enterprises specializing in gene technology, digital medicine, biomedicine etc. The fund mainly aims on projects in the initial stage and early stage of growth, supplemented by projects in the middle and late stages of growth, so as to achieve reasonable allocation in the project investment stage.

BGI Co-Win relies on the resources of partners such as BGI Group and its past successful investment partners in life sciences, to provide industry development coordination, and provide legal, financial, human resources and other services for the invested projects, so as to help the invested projects improve their operation and management capabilities and achieve stable and sustainable development.

At present, BGI Co-Win’s investments ranges from treatment, diagnosis, prevention to health management, from new technology and new platform of IVD, new application scenarios of NGS, to key components of the industrial supply chain; from Cellomics to nucleic acid drugs, polypeptide drugs, cell/gene therapy, synthesis and other fields, with constantly creating value for customers and achieving mutual benefit and co-win results.